Pre-Rolls, Vapes, and What Product Share Shifts Predict

Photo by Dad Grass via Pexels.

Walk into a dispensary in Denver or Detroit right now and the flower wall is still the anchor of the store. That's not an illusion: flower remains the single largest category in tracked US cannabis sales, holding 39.4% of the market and roughly $9.6 billion in annual revenue. If you only looked at that number, you'd conclude nothing has changed. But market share is a lagging indicator, and the growth curves sitting underneath that flower number tell a different story than the topline suggests.

Pre-rolls hit 15.9% of tracked US sales in the first quarter of 2026, up 9.8% year over year, and according to Headset's state-by-state breakdowns, that gain showed up in every single tracked market -- not a regional fluke, not a California-only trend. Look north to Canada, a legal market that's had a few more years to mature under one uniform federal framework, and pre-rolls have already overtaken flower entirely, claiming 32.4% of sales to become the largest category outright. That's not proof the US will follow the same path on the same timeline, but it's a real, observable data point about what a cannabis market looks like once it's had time to settle.

Put those threads together and a pattern emerges that cuts across pre-rolls, vape, and even the tiny-but-fast-growing beverage category: consumers are increasingly paying for convenience and engineering, not raw plant material. That has real consequences for who wins and loses as the market matures -- cultivators growing beautiful flower are competing against processors who can turn that same flower into a pre-measured, infused, shelf-stable product a casual buyer can grab without thinking. This piece works through where that shift is showing up hardest, where it's stalling, and what two regulatory events landing in mid-to-late 2026 could do to accelerate or blunt it.

Pre-Rolls Are Eating the Market, One State at a Time

Photo by 2H Media via Unsplash.

The pre-roll numbers are worth sitting with because they're consistent in a way that few cannabis category trends are. Headset's data shows the format climbing to 15.9% of tracked US sales in Q1 2026, a 9.8% jump from the same quarter a year earlier, and critically, that gain wasn't concentrated in one or two mature markets -- it showed up in every state Headset tracks. That kind of uniformity is rare in an industry this fragmented, and it suggests something structural rather than a regional promotional push.

Custom Cones USA, working off 2025 Headset figures, put the category at $3.6 billion in sales and 383 million units sold that year, with a 2026 forecast pushing toward $4 billion and a longer trajectory clearing $5.2 billion by 2030. Those are real, cited figures, not projections pulled from thin air, though it's worth flagging that any multi-year forecast carries the usual caveats about assuming current adoption curves hold steady.

The more interesting detail sits inside the category breakdown. Infused pre-rolls -- flower or cones dosed with kief, rosin, or distillate -- now account for 48.5% of category revenue, and multipacks make up 54.2% of units sold. That means the growth isn't really about people rediscovering rolled flower; it's about a manufactured, standardized, often more potent product replacing the DIY grind-and-roll experience entirely. A five-pack of identical 0.5-gram infused pre-rolls is a fundamentally different purchase decision than an eighth of loose flower -- it's closer to buying a six-pack of beer than buying hops.

Canada offers a preview, with the obvious caveat that it's a preview, not a guarantee. Its pre-roll category has already overtaken flower outright at 32.4% of sales, in a market that legalized federally in 2018 and has had years to standardize under one regulatory framework. If US infused-multipack adoption tracks a similar curve, pre-rolls could realistically challenge flower for the top category spot within several years -- not overnight, but on a timeline measured in single-digit years rather than decades.

The counter-case matters just as much. The US isn't one market; it's 39 separate state-regulated markets with different tax structures, potency caps, and testing regimes, and that fragmentation is exactly the kind of friction that slowed uniform category shifts in the past. Canada could hit 32.4% because one Health Canada framework applied everywhere at once. A California multipack rule doesn't touch Texas or Florida. Expect the US pre-roll surge to keep climbing, but expect it to arrive unevenly, market by market, rather than all at once.

Vape's Quiet Comeback: Disposables, Live Resin, and Two-Gram Carts

Flower and vapes still dominate US cannabis sales in Q1 2026, together accounting for over 65% of tracked sales, while pre-rolls have risen to a strong third place with nearly 16% share, well ahead of concentrates, topicals, and capsules.

Vape has quietly become the top-selling category in two of the country's most closely watched markets. BDSA data shows vape has now surpassed flower in both California and Washington -- two states with long legal histories and sophisticated consumer bases, which makes the shift more meaningful than if it had happened in a newer, smaller market still figuring out its habits.

Inside the vape category itself, there's been a format handoff worth noting: disposables have overtaken cartridges as the leading vape format for the first time. That's a real inflection point, because cartridges required a reusable battery and a bit of ongoing maintenance, while disposables are single-use, grab-and-go devices. The single fastest-growing format size within that shift is the 2-gram disposable, which has doubled its share of the category in just two years -- consumers aren't just choosing disposable over refillable, they're choosing bigger disposable units that reduce how often they need to repurchase.

At the same time, oil quality is trading up. Live resin and other premium, less-processed oil types are gaining share at the direct expense of distillate, with live resin hitting a 2026 high of 28% category share in May. Distillate is cheaper to produce and easier to standardize, but it strips out the terpene profile that live resin preserves, and consumers -- particularly more experienced ones -- have clearly started paying a premium to get that flavor and effect profile back.

Put both trends together and you get a category worth roughly $8 billion in retail sales over the 12 months ending May 2026, representing 26% of total retail and growing 6% year over year. That's not explosive growth compared to pre-rolls or beverages, but it's growth at scale, in the single largest dollar category in the industry.

What this predicts, read carefully, is two simultaneous and seemingly contradictory movements: consumers trading up in quality (live resin over distillate) while also trading up in convenience (disposable over refillable). Historically those two impulses pull against each other -- quality-focused buyers tend to tolerate more friction, convenience-focused buyers tend to accept lower quality. Vape consumers appear to be demanding both at once, which is a meaningfully higher bar for manufacturers, and it's likely why premium disposable brands able to deliver live-resin-quality oil in a single-use format are commanding real pricing power right now.

Beverages Are Small but Growing Fastest, and Summer Proves It

Photo by Elsa Olofsson via Pexels.

Beverages are still a rounding error next to flower and vape in absolute dollar terms, but the growth rate is the outlier that deserves attention. BDSA reported cannabis beverages grew 15% year over year nationally in Q1 2025, and that national figure undersells what's happening in specific state markets. Michigan posted 112% growth, Ohio 79%, and Illinois 47% -- numbers that look less like organic category maturation and more like a format still finding its shelf space and its customer.

New York's monthly data makes the seasonality argument almost by itself. Beverage sales there swung from $341,000 in February to a July peak of $708,000 -- more than doubling across five months, tracking almost exactly with warm-weather social occasions: cookouts, boat days, backyard gatherings, the kind of low-commitment social drinking occasion that a can fits into far more naturally than a joint or a dab rig does.

That seasonality is itself informative about what beverages are actually competing against. A flower purchase or a vape cart purchase doesn't swing 2x based on the calendar the way a canned seltzer does. Beverages are behaving like a beverage -- following the same warm-weather curve that non-alcoholic and alcoholic drink categories have followed for decades -- rather than like a traditional cannabis format tied to habitual daily use.

Because the category remains small in absolute share, its outsized percentage growth needs a caveat that gets lost in headline numbers: growing 112% off a tiny base is a very different achievement than growing 10% off a multi-billion-dollar base like flower or vape. Beverages are still finding their footing, and there's a real chance some of these state-level surges moderate once the category has had a full multi-year cycle rather than a single fast-growth stretch.

The open question that matters more than the growth rate itself is who's actually buying these cans. Are beverages pulling in people who otherwise weren't cannabis consumers at all -- the alcohol-curious, sober-curious crowd looking for a lower-proof social option -- or are they mostly existing flower and vape customers adding a new occasion to their existing habit, say a Tuesday night can on top of their regular vape use, without reducing spend elsewhere? The data as it currently stands can't cleanly separate those two stories, and the answer matters enormously for how big this category can eventually get. New-consumer growth expands the total market; occasion-addition growth just redistributes existing dollars.

What's Losing Ground: Concentrates, Capsules, and Topicals

Photo by devansiennaescrow via Pixabay.

Not every processed, more-engineered format is winning, which is an important check against any narrative that says convenience simply always wins. Concentrates are down 7.7% year over year, capsules are down 24.6%, and topicals are down 13.8%, according to Headset. All three require something the growth categories don't: a bit of specialized knowledge or a specific ritual before you can use them.

Dabbing concentrates means owning a rig, a torch or e-nail, and knowing how to manage temperature -- a real barrier for anyone who didn't come up through legacy cannabis culture. Capsules require thinking in milligrams and waiting 60-90 minutes for onset, which is a much harder sell next to a vape hit that works in seconds. Topicals occupy an even narrower lane, mostly localized pain relief rather than a recreational experience, which caps their addressable audience by design.

The concentrates decline deserves a more careful read than a simple category-in-freefall headline. Concentrate, as raw material, is the literal input for infused pre-rolls and vape cartridge oil -- the kief coating a pre-roll or the distillate filling a cart both start life as a concentrate before they're repackaged into a different SKU. So a chunk of what looks like concentrate demand disappearing is really concentrate demand migrating into a form factor consumers find easier to use, showing up instead as growth in the pre-roll and vape numbers covered above. The raw category is shrinking; the underlying extraction and processing business behind it likely isn't shrinking nearly as much, because that same oil and kief is still getting made -- it's just getting sold to consumers wrapped in paper or loaded into a cartridge rather than sold as a dab in a jar.

Capsules and topicals losing the most ground of any tracked category tells a related but distinct story: the medical-style, precisely-dosed, non-inhalation segment of the market is shrinking relative to formats built for fast onset and recreational use. That's consistent with a broader maturation pattern seen in state markets that started medical-only and later added adult-use sales -- once a recreational customer base arrives in volume, it tends to outgrow and eventually dwarf the smaller, more clinical medical segment that the market originally launched to serve, even in states where medical sales never technically disappeared.

The Regulatory Wildcard: Rescheduling and the Hemp THC Cap

Photo by RDNE Stock project via Pexels.

Two regulatory events landing within months of each other in 2026 could matter more to these category trends than any organic shift in consumer taste. On April 23, 2026, Acting Attorney General Todd Blanche issued an order placing FDA-approved marijuana products and state-licensed medical marijuana products in Schedule III. That's a narrower move than full descheduling, but it's a formal, documented federal action -- not speculation -- and it sets up the next step: a DEA hearing on recreational marijuana scheduled for June 29 through July 15, 2026, at the DEA Hearing Facility in Arlington, Virginia.

History is useful here for calibrating expectations. Formal DEA hearings of this kind have historically preceded major reclassification decisions, but they've never produced instant, market-wide change. The state-by-state rollout of medical marijuana programs from the 1990s through the 2000s took roughly two decades to cover a meaningful share of the country, and Canada's shift from medical-only to full federal legalization in 2018 was itself the product of a multi-year legislative and judicial process, not a single announcement. The reasonable extrapolation from that pattern is that scheduling changes in 2026 play out incrementally over multiple years -- reshaping banking access, tax treatment under IRS code section 280E, and interstate research long before they reshape which product format sits on a dispensary shelf.

The more immediate wildcard for the categories discussed above is a narrower, less glamorous rule: a federal hemp-derived THC regulation effective November 12, 2026, that replaces the current delta-9 concentration test with a total-THC standard and caps any single container at 0.4 milligrams. If that rule holds as written, it would sharply restrict the hemp-derived beverages and gummies currently sold outside the licensed dispensary system -- often at gas stations and grocery stores, and often at prices that undercut licensed dispensary beverages and edibles because they skip state cannabis taxes and licensing costs entirely.

Follow that thread and a reasoned prediction emerges: if the 0.4mg cap sticks, licensed dispensary beverages and infused pre-rolls gain a real competitive opening against the unregulated hemp THC drinks that have been undercutting them on price, which could accelerate the kind of beverage growth already showing up in Michigan and Ohio. But this is a prediction, not a certainty, and the hemp industry has a track record worth noting: it fought hard against delta-8 restrictions at the state level in past years, winning carve-outs and delays in multiple states. A similar legal and lobbying push against the 0.4mg cap could soften or delay enforcement well past the November 2026 effective date, so this is one to watch rather than bank on.

Line up every category gaining share -- infused multipack pre-rolls, live-resin disposables, ready-to-drink cans -- and the common thread isn't potency or price, it's predictability. Consumers are increasingly paying for someone else to have already done the measuring, the rolling, the extraction, and the quality control, rather than buying raw flower and doing that work themselves. Concentrates, capsules, and topicals losing ground fits the same pattern in reverse: those formats ask the consumer to supply the expertise, and fewer are willing to.

That shift has a clear winner and a clear loser embedded in it. It favors processors, formulation labs, and brands with real packaging and engineering chops over cultivators whose value proposition is simply growing good flower. This isn't a new story in intoxicant markets -- it's essentially a rerun of what happened in alcohol, where craft brewing coexists with a much larger ready-to-drink and spirits-based seltzer market, and in tobacco, where hand-rolled cigarettes gave way almost entirely to machine-manufactured cigarettes a century ago. Raw agricultural output rarely stays the highest-margin part of a maturing consumer market for long; the processing and branding layer captures more of the value as the market ages.

None of this is guaranteed to unfold on the clean timeline the data might suggest. Watch November 12, 2026, and the outcome of the DEA's July hearing together, because either one could move faster than organic consumer preference alone. If the hemp THC cap holds, licensed beverages and infused pre-rolls get a real price and legitimacy advantage almost overnight. If federal scheduling moves further and faster than the historical state-by-state and Canadian precedents suggest it should, banking, taxation, and interstate commerce could all shift in ways that scramble which companies are positioned to capture this move toward engineered convenience. The category data tells you where consumers are heading; the regulatory calendar over the next twelve months will tell you how fast they get there.